SE0202464D0 - Use of compounds - Google Patents

Use of compounds

Info

Publication number
SE0202464D0
SE0202464D0 SE0202464A SE0202464A SE0202464D0 SE 0202464 D0 SE0202464 D0 SE 0202464D0 SE 0202464 A SE0202464 A SE 0202464A SE 0202464 A SE0202464 A SE 0202464A SE 0202464 D0 SE0202464 D0 SE 0202464D0
Authority
SE
Sweden
Prior art keywords
diseases
driven
compounds
conditions
cell
Prior art date
Application number
SE0202464A
Other languages
English (en)
Inventor
Per-Olof Ericsson
Karin Kristensson
Pascalis Sideras
Peter Sjoe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0202464A priority Critical patent/SE0202464D0/sv
Publication of SE0202464D0 publication Critical patent/SE0202464D0/sv
Priority to PCT/SE2003/001274 priority patent/WO2004016270A1/en
Priority to AU2003251271A priority patent/AU2003251271A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0202464A 2002-08-14 2002-08-14 Use of compounds SE0202464D0 (sv)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE0202464A SE0202464D0 (sv) 2002-08-14 2002-08-14 Use of compounds
PCT/SE2003/001274 WO2004016270A1 (en) 2002-08-14 2003-08-13 USE OF Itk INHIBITORS FOR THE TREATMENT OF MAST CELL-DRIVEN OR BASOPHIL-DRIVEN DISEASES
AU2003251271A AU2003251271A1 (en) 2002-08-14 2003-08-13 USE OF Itk INHIBITORS FOR THE TREATMENT OF MAST CELL-DRIVEN OR BASOPHIL-DRIVEN DISEASES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202464A SE0202464D0 (sv) 2002-08-14 2002-08-14 Use of compounds

Publications (1)

Publication Number Publication Date
SE0202464D0 true SE0202464D0 (sv) 2002-08-14

Family

ID=20288752

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0202464A SE0202464D0 (sv) 2002-08-14 2002-08-14 Use of compounds

Country Status (3)

Country Link
AU (1) AU2003251271A1 (sv)
SE (1) SE0202464D0 (sv)
WO (1) WO2004016270A1 (sv)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2564568A1 (en) * 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy
WO2013153539A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors
CN103804381A (zh) * 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
ES2875737T3 (es) 2015-02-02 2021-11-11 Kancera Ab Derivados de 2-fenil-3H-imidazo[4,5-b]piridina útiles como inhibidores de la actividad tirosina quinasa de ROR1 de mamíferos
US11660303B2 (en) 2016-07-11 2023-05-30 Kancera Ab 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
WO2018011138A1 (en) 2016-07-11 2018-01-18 Kancera Ab 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024035A1 (en) * 1997-11-10 1999-05-20 Bristol-Myers Squibb Company Benzothiazole protein tyrosine kinase inhibitors
DE60039059D1 (de) * 1999-10-07 2008-07-10 Amgen Inc Triazin-kinase-hemmer
SK287882B6 (sk) * 1999-12-24 2012-02-03 Aventis Pharma Limited Azaindoles derivatives, pharmaceutical composition containing thereof and their use
HUP0303538A2 (hu) * 2000-12-21 2005-02-28 Bristol-Myers Squibb Co. Tirozin kinázok Tec családjának tiazolil-vegyület inhibitorai és ezeket tartalmazó gyógyszerkészítmények

Also Published As

Publication number Publication date
WO2004016270A1 (en) 2004-02-26
AU2003251271A1 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
NO20052928L (no) Nye kjemiske forbindelser
MX2009006267A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa.
UA97474C2 (ru) Соединения для лечения нарушений, связанных с активностью dgat1
ATE441418T1 (de) Verwendung von treprostinil zur verbesserung der nierenfunktion
NO20072747L (no) Fremgangsmate for fremstilling av indazolforbindelser
NO20064895L (no) 6,6-Bisykliske ring-substituerte heterobisykliske protein-kinase inhibitorer
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
MX2010000617A (es) Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
EA200801372A1 (ru) Способы получения замещенных пиримидинов
DK1543011T3 (da) Thienopyrrolyl- og furanopyrrolylforbindelser og deres anvendelse som histamin H4-receptorligander
HRP20020748A2 (en) Substituted beta-carbolines with ikb-kinase inhibiting activity
WO2007109045A8 (en) Heterocyclic organic compounds for the treatment of in particular melanoma
EA201100427A1 (ru) Гетероциклические ингибиторы киназы
TW200801008A (en) Protein kinase inhibitors
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
WO2006034113A3 (en) Quinolone analogs as cell proliferation inhibitors
NO20054371L (no) Somatostatin-dopamin kimaere analoger
IL190730A0 (en) Potassium channel inhibitors
ATE547396T1 (de) Dicycloalkylcarbamoyl-harnstoffe als glucokinase- aktivatoren
NO20080061L (no) Imidazolyl-pyrimidinforbindelser for anvendelse til behandling av proliferative lidelser
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
MX2010005650A (es) Derivados de diazabicicloalcano substituidos con biarilo.
SE0202464D0 (sv) Use of compounds
NO20080553L (no) Azinyl-3-sulfonylindazolderivater som 5-hydroksytrypyamin-6 ligander
ATE410235T1 (de) Behandlung von ballastwasser